Skip to main content

Grafa News and Videos — Page 1193

Latest

Grafa

NervGen gene therapy slashes functional deficits in spinal cord injury trial

NervGen Pharma (NYSE:NGEN) reported positive results from an independent, blinded biomechanical gait analysis of its Phase 1b/2a CONNECT SCI study, demonstrating that its lead candidate, NVG-291, achieved statistically significant improvements in walking quality among chronic spinal cord injury patients.

Read more: NervGen gene therapy slashes functional deficits in spinal cord injury trial

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift